Citations

Clear

6273 citation(s) found for "To, Andrew".

OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY
Jakopsen, L.H., Nowakowski, G. S., Ansell, Steven M., Thompson, Chester Andrew , Jørgensen, Judit , Frederiksen, Henrik , Novak, Anne J. , Frederiksen, Henrik , Maurer, Matthew J. , Habermann, Thomas M. , Brown, Peter de Nully , Syrbu, Sergei , Feldman, Andrew L. , Rimsza, Lisa M. , Cerhan, James R. , El‐Galaly, Tarec Christoffer , Link, Brian K.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 231-232

10.1002/hon.44_2630 Get It

Symptomatic and Radiographic Manifestations of Kidney Stone Recurrence and Their Prediction by Risk Factors: A Prospective Cohort Study
D’Costa, Matthew R. , Haley, William E. , Mara, Kristin C. , Vrtiska, Terri J., Pais, Vernon M., Jacobsen, Steven J. , Rule, Andrew D. , Rule, Andrew D , Haley, William E , D'Costa, Matthew , Mara, Kristin C , Enders, Felicity , McCollough, Cynthia H. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | June 7, 2019 | Volume: 30 | Issue: 7 | Pages: 1251-1260

10.1681/asn.2018121241 | PMID 31175141 Get It

Significance Statement Kidney stone recurrence can manifest with symptoms from stone passage or with asymptomatic changes in kidney stone burden revealed by radiography. In a multicenter, prospective cohort study, the authors demonstrate that substantially more asymptomatic and self-managed symptomatic kidney stone recurrence occur in stone formers than has been appreciated, as many studies consider only symptomatic recurrence that results in clinical care. Among first-time symptomatic stone formers, 54% had an asymptomatic kidney stone; half of those with such a stone passed it within 5 years (but only half who did so experienced symptoms). The findings also show that when a more comprehensive definition of recurrence that includes all symptomatic and radiological manifestations is used, risk factors better predict kidney stone recurrence, thus supporting a comprehensive assessment of recurrence in clinical trials. Background Meaningful interpretation of changes in radiographic kidney stone burden requires understanding how radiographic recurrence relates to symptomatic recurrence and how established risk factors predict these different manifestations of recurrence. Methods We recruited first-time symptomatic stone formers from the general community in Minnesota and Florida. Baseline and 5-year follow-up study visits included computed tomography scans, surveys, and medical record review. We noted symptomatic recurrence detected by clinical care (through chart review) or self-report, and radiographic recurrence of any new stone, stone growth, or stone passage (comparing baseline and follow-up scans). To assess the prediction of different manifestations of recurrence, we used the Recurrence of Kidney Stone (ROKS) score, which sums multiple baseline risk factors. Results Among 175 stone formers, 19% had symptomatic recurrence detected by clinical care and 25% detected by self-report; radiographic recurrence manifested as a new stone in 35%, stone growth in 24%, and stone passage in 27%. Among those with a baseline asymptomatic stone (54%), at 5 years, 51% had radiographic evidence of stone passage (accompanied by symptoms in only 52%). Imaging evidence of a new stone or stone passage more strongly associated with symptomatic recurrence detected by clinical care than by self-report. The ROKS score weakly predicted one manifestation—symptomatic recurrence resulting in clinical care ( c -statistic, 0.63; 95% confidence interval, 0.52 to 0.73)—but strongly predicted any manifestation of symptomatic or radiographic recurrence (5-year rate, 67%; c -statistic, 0.79; 95% confidence interval, 0.72 to 0.86). Conclusions Recurrence after the first stone episode is both more common and more predictable when all manifestations of recurrence (symptomatic and radiographic) are considered.
The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype
Hari, Priya, Millar, Fraser R. , Tarrats, Núria , Birch, Jodie , Quintanilla, Andrea , Rink, Curtis, Fernández-Duran, Irene , Muir, Morwenna , Finch, Andrew J. , Brunton, Valerie G. , Passos, João F. , Morton, Jennifer P. , Boulter, Luke , Acosta, Juan Carlos , Passos, João F

Mayo Clinic

Science Advances | June 5, 2019 | Volume: 5 | Issue: 6 | Pages: No page available

10.1126/sciadv.aaw0254 | PMID 31183403 Get It

Innate immune sensing is essential for the proinflammatory program in cellular senescence.
Eosinophils downregulate lung alloimmunity by decreasing TCR signal transduction
Onyema, Oscar Okwudiri , Guo, Yizhan , Mahgoub, Bayan , Wang, Qing , Manafi, Amir , Mei, Zhongcheng , Banerjee, Anirban , Li, Dongge , Stoler, Mark H. , Zaidi, Melissa T. , Schrum, Adam G. , Kreisel, Daniel , Jacobsen, Elizabeth A. , Krupnick, Alexander S. , Schrum, Adam G , Jacobsen, Elizabeth A , Gelman, Andrew E

Mayo Clinic

JCI Insight | June 5, 2019 | Volume: 4 | Issue: 11 | Pages: No page available

10.1172/jci.insight.128241 | PMID 31167966 Get It

Despite the accepted notion that granulocytes play a universally destructive role in organ and tissue grafts, it has been recently described that eosinophils can facilitate immunosuppression-mediated acceptance of murine lung allografts. The mechanism of eosinophil-mediated tolerance, or their role in regulating alloimmune responses in the absence of immunosuppression, remains unknown. Using lung transplants in a fully MHC-mismatched BALB/c (H2 d ) to C57BL/6 (H2 b ) strain combination, we demonstrate that eosinophils downregulate T cell–mediated immune responses and play a tolerogenic role even in the absence of immunosuppression. We further show that such downregulation depends on PD-L1/PD-1–mediated synapse formation between eosinophils and T cells. We also demonstrate that eosinophils suppress T lymphocyte responses through the inhibition of T cell receptor/CD3 (TCR/CD3) subunit association and signal transduction in an inducible NOS–dependent manner. Increasing local eosinophil concentration, through administration of intratracheal eotaxin and IL-5, can ameliorate alloimmune responses in the lung allograft. Thus, our data indicate that eosinophil mobilization may be utilized as a novel means of lung allograft–specific immunosuppression.
Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction
Lee, Justin Z. , Amin, Mustapha, Neville, Matthew R., Almader‐Douglas, Diana , Killu, Ammar M. , Madhavan, Malini , Cha, Yong‐Mei , Asirvatham, Samuel J. , Friedman, Paul A. , Mulpuru, Siva K. , Tseng, Andrew S. , Kunze, Katie L. , Almader-Douglas, Diana, Asirvatham, Samuel J , Gersh, Bernard J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | June 4, 2019 | Volume: 12 | Issue: 6 | Pages: No page available

10.1161/circep.118.006951 | PMID 31159582 Get It

Background: The treatment of heart failure with reduced ejection fraction has been the subject of numerous randomized controlled trials involving medications and cardiac implantable electronic device therapies. As newer effective pharmacological therapies suggest significant reductions in all-cause mortality, the role of additional device therapy in heart failure with reduced ejection fraction deserves further scrutiny. Methods: A systematic review and network meta-analysis on the effect of medication and device therapies in heart failure with reduced ejection fraction on all-cause mortality was performed. Randomized controlled trials published between January 1980 and July 2017 were identified using Medline, EMBASE, and Cochrane Controlled Register of Trials databases. Pcnetmeta package in R was used to calculate treatment arm–based estimated rates, rate ratios, and probability ranks with 95% credible intervals. Results: Combination therapy of ACE (angiotensin-converting enzyme) inhibitors or ARBs (angiotensin receptor blockers) with β-blockers (BBs) alone or in addition to implantable cardiac defibrillators or cardiac resynchronization therapy with defibrillators demonstrated a significant reduction of all-cause mortality when compared with placebo. By probability rank, implantable cardiac defibrillator+ACE inhibitor or ARB+BB+mineralocorticoid receptor antagonist, implantable cardiac defibrillator+ACE inhibitor or ARB+BB, and angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist combination therapies have the highest probability of being ranked the best treatment. There was no significant difference in the rate of mortality when comparing angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antagonist to implantable cardiac defibrillator+optimal pharmacological combination therapy. Conclusions: BB and renin-angiotensin system blockers alone or in combination with defibrillator device therapy have robust evidence for a reduction in mortality compared with placebo. The comparative efficacy of pharmacological therapy with angiotensin receptor-neprilysin inhibitors and device therapy deserves further investigation.
Test collections for electronic health record-based clinical information retrieval
Wang, Yanshan , Hersh, William , Liu, Sijia , Hersh, William , Wen, Andrew , Bedrick, Steven , Liu, Hongfang , Wang, Yanshan

Mayo Clinic

JAMIA Open | June 4, 2019 | Volume: 2 | Issue: 3 | Pages: 360-368

10.1093/jamiaopen/ooz016 | PMID 31709390 Get It

AbstractObjectivesTo create test collections for evaluating clinical information retrieval (IR) systems and advancing clinical IR research.Materials and MethodsElectronic health record (EHR) data, including structured and free-text data, from 45 000 patients who are a part of the Mayo Clinic Biobank cohort was retrieved from the clinical data warehouse. The clinical IR system indexed a total of 42 million free-text EHR documents. The search queries consisted of 56 topics developed through a collaboration between Mayo Clinic and Oregon Health & Science University. We described the creation of test collections, including a to-be-evaluated document pool using five retrieval models, and human assessment guidelines. We analyzed the relevance judgment results in terms of human agreement and time spent, and results of three levels of relevance, and reported performance of five retrieval models.ResultsThe two judges had a moderate overall agreement with a Kappa value of 0.49, spent a consistent amount of time judging the relevance, and were able to identify easy and difficult topics. The conventional retrieval model performed best on most topics while a concept-based retrieval model had better performance on the topics requiring conceptual level retrieval.DiscussionIR can provide an alternate approach to leveraging clinical narratives for patient information discovery as it is less dependent on semantics. Our study showed the feasibility of test collections along with a few challenges.ConclusionThe conventional test collections for evaluating the IR system show potential for successfully evaluating clinical IR systems with a few challenges to be investigated.
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
Dempsey, Timothy , Sangaralingham, Lindsey R. , Yao, Xiaoxi , Sanghavi, Darshak , Shah, Nilay D. , Dempsey, Timothy M , Yao, Xiaoxi , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 31, 2019 | Volume: 200 | Issue: 2 | Pages: 168-174

10.1164/rccm.201902-0456oc | PMID 31150266 Get It

Abstract Rationale Since their approval, there has been no real-world or randomized trial evidence evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically important outcomes such as mortality and hospitalizations. Objectives To evaluate the clinical effectiveness of the antifibrotic medications pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Methods Using a large U.S. insurance database, we identified 8,098 patients with idiopathic pulmonary fibrosis between October 1, 2014 and March 1, 2018. A one-to-one propensity score–matched cohort was created to compare patients treated with antifibrotic medications (n = 1,255) with those not on treatment (n = 1,255). The primary outcome was all-cause mortality. The secondary outcome was acute hospitalizations. Subgroup analyses were performed to evaluate mortality differences by drug. Measurements and Main Results The use of antifibrotic medications was associated with a decreased risk of all-cause mortality (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62–0.98; P value = 0.034). However, this association was present only through the first 2 years of treatment. There was also a decrease in acute hospitalizations in the treated cohort (HR, 0.70; 95% CI, 0.61–0.80; P value <0.001). There was no significant difference in all-cause mortality between patients receiving pirfenidone and those on nintedanib (HR, 1.14; 95% CI, 0.79–1.65; P = 0.471). Conclusions Among patients with idiopathic pulmonary fibrosis, antifibrotic agents may be associated with a lower risk of all-cause mortality and hospitalization compared with no treatment. Future research should test the hypothesis that these treatments reduce early, but not long-term, mortality as demonstrated in our study.
DCE‐MRI protocol for constraining absolute pharmacokinetic modeling errors within specific accuracy limits
Knight, Silvin P. , Meaney, James F. , Fagan, Andrew , Fagan, Andrew J

Mayo Clinic

Medical Physics | May 31, 2019 | Volume: 46 | Issue: 8 | Pages: 3592-3602

10.1002/mp.13635 | PMID 31148187 Get It

PurposeTo quantify the effects of DCE acquisition and pharmacokinetic modeling processing methodologies on the absolute accuracy and precision of derived pharmacokinetic (PK) parameter values using a novel anthropomorphic phantom test device in which “ground truth” values were known a priori.MethodsGround truth arterial input function (AIF), tumor, and healthy tissue contrast agent concentration‐time curves (CTCs) were established within the phantom and repeatedly measured on a 3T MRI scanner with varying temporal resolution (Tres = 1.22–30.6 s). Ground truth CTCs, Ktrans, ve, and kep values were directly compared to measured values as a function of Tres, with and without the application of voxel‐wise flip‐angle corrections applied to the data and PK modeling performed using linear and nonlinear forms of the standard Tofts model.ResultsMeasurement of the AIF was strongly affected by the Tres used (AIF curve‐shape feature errors: 3%–222% for Tres: 1.22–30.6 s), which directly translated to errors in the derived Ktrans, ve, and kep values of 1%–24%, 2%–5%, and 1%–26% respectively across this Tres range (flip‐angle correction applied). Further appreciable improvements in accuracy and precision arising from the use of flip angle corrections and nonlinear least squares fitting were quantified and used to identify optimal acquisition and analysis methodologies for which measurement errors could be constrained below threshold levels.ConclusionThis quantitative study provides insight into how errors in AIF measurement propagate to errors in PK parameter outputs. Absolute quantification of the accuracy and precision of MR‐measured CTCs, and resultant PK parameter values, allowed for an optimal temporal resolution to be defined commensurate with maintaining Ktrans, ve, and kep measurement errors below 5% and 10% levels. An appreciable gain in PK parameter estimation accuracy at the analysis stage was also demonstrated using flip‐angle corrections and a linear approach to PK model fitting.
Effect of the location of the split of the subscapularis on range of motion and stability of the glenohumeral joint following Latarjet or Trillat procedures
Nourissat, Geoffroy , Hooke, Alex, Berglund, Lars , Thoreson, Andrew R. , An, K-N, Werthel, J-D., Hooke, Alexander W. , An, K-N.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | May 30, 2019 | Volume: 7 | Issue: 5_suppl3 | Pages: No page available

10.1177/2325967119s00202 Get It

Aim: Compare the effect of Latarjet and Trillat procedures on glenohumeral stability and range of motion. Background: Little is known about the impact of the location of the sling effect on joint stability and range of motion. Methods: 12 cadaveric shoulders were cleaned of soft tissue except for the subscapularis, conjoined tendon, and anterior capsule. A custom-made apparatus generating anterior humeral translation and joint compression was used. The machine applied compression load in the medial direction. The subscapularis and conjoint tendon were loaded. Internal/external range of motion and joint stability were assessed at 0°, 30° and 60° glenohumeral abduction. Range of motion was assessed by rotating the humeral shaft. Joint stability was assessed at maximum external rotation, translating the humerus. Specimen were tested in five conditions: 1) intact shoulder, 2) 6-mm bony glenoid defect (20% defect) 3) Trillat procedure, 4) Latarjet procedure with subscapularis split at the junction between its superior 2/3rds and inferior 1/3 rd, 5) Latarjet procedure with subscapularis split at the superior 1/3rds and inferior 2/3rds. Means were compared with a full factorial-repeated measures ANOVA with pairwise post hoc comparisons. Results: Peak translation force and stability ratio were significantly lower with the glenoid defect when compared to the intact and all the repaired conditions at all levels of glenohumeral abduction. The level of the subscapularis split had no significant influence on these values and no significant difference could be found between Trillat and Latarjet procedures. Range of motion in internal and external rotation were not significantly different between the different conditions. Conclusions: Joint stability and range of motion after a Latarjet are not impacted by the location of the subscapularis muscle split. Trillat and Latarjet techniques provide comparable stabilization of the joint, even in the presence of a critical bony defect of the glenoid.